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Purpose: To develop a gastroretentive formulation of bupropion hydrochloride in the form of floating 
tablets. 
Methods: Floating tablets were prepared by wet granulation method using various amounts of sodium 
carboxymethycellulose (NaCMC), different molecular weight grade of hydroxypropyl methylcellulose 
(HPMC) and varying amounts of fillers (microcrystalline cellulose, lactose and tricalcium phosphate). 
Sodium bicarbonate was also incorporated as the gas-generating agent. The formulations were tested 
for their physical properties, floating lag time, duration of floating and in-vitro drug release. 
Results: All the tablet formulations containing either HPMC K4M or HPMC K15M as the sustained-
release polymer together with either microcrystalline cellulose (MCC) or lactose, floated in the release 
medium for > 10 h. Tablets prepared with MCC released ≥ 79 % of the drug after 10 h, while those 
prepared with lactose released ≥ 85 % of the drug within the same period. Tablets containing NaCMC 
alone did not show good floating properties but when HPMC K4M was also incorporated at certain 
ratios, tablets with good floating behavior and suitable drug release patterns were produced. Drug 
release kinetic studies showed that formulations fitted best to the Higuchi model.  
Conclusion: The developed floating tablets of bupropion HCl exhibited prolonged drug release for ≥ 10 
h, and, thus may improve bioavailability and minimize fluctuations in plasma drug concentration. 
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INTRODUCTION 
 
One of the problems associated with oral 
sustained release systems is that they do not 
remain for long in the upper gastrointestinal 
tract (GIT) which is the main absorption 
region for most drugs. Thus, rapid 
gastrointestinal transit can prevent complete 
drug release in the absorption zone and this 
may lead to reduction in drug bioavailability 
and efficacy of administered dose [1]. 
However, the development of gastroretentive 
drug delivery systems (GRDDS) can 
overcome this problem. GDDS are capable of 
being retained in the stomach for a long 
period of time while they release the drug in a 
sustained manner for continuous delivery to 
its absorption site in the upper GIT [2].  
  
Various approaches have been employed to 
increase the retention of oral dosage forms in 
the stomach. One of the most common 
approaches is to formulate floating drug 
delivery systems (FDDS) [3]. FDDS have a 
bulk density lower than gastric fluids and thus 
remain buoyant in the stomach without 
affecting the gastric emptying time for a 
prolonged time [4].  
 
Bupropion is a atypical antidepressant widely 
used in major depressive disorders and 
smoking recession [5]. In the treatment of 
depression, multiple dosing is required. Many 
of its adverse effects are dose-dependent, 
and hence a prolonged-release dosage form 
would improve patient compliance and 
tolerability. Moreover, it is expected that a 
gastroretentive dosage form of bupropion HCl 
would provide more predictable bioavailability 
and better control of the fluctuations in drug 
plasma concentrations. 
 
The objective of the present study was to 
develop bupropion HCl floating matrix tablets 
for prolonged retention and drug release in 
the stomach, as well as for improved drug 
availability and reduced fluctuation of the 







Bupropion HCl (Eczacibazsi, Turkey) and 
HPMC (Methocel K4M, K15M Colorcon, 
England) were used as drug and matrix 
former, respectively..NaCMC (3000 cps), 
lactose, tricalcium phosphate, 
polyvinylpyrrolidone K-10, sodium 
bicarbonate and magnesium stearate were all 
obtained from Merck, Germany. 
Microcrystalline cellulose (Avicel PH 102) 
was produced by FMC Corporation. 
 
Preparation and characterization of matrix 
tablets  
 
Matrix tablets containing 150 mg bupropion 
HCl powder along with various amounts of 
HPMC K4M, HPMC 15M or NaCMC plus 
fillers (MCC, lactose and tricalcium 
phosphate) were prepared (as per the 
compositions in Tables 1 and 2) by 
compression in a single-punch tablet 
machine (Erweka, Germany) equipped with 
12 mm flat-faced punches. Since bupropion 
HCl shows poor compressibility and 
flowability, wet granulation was used to 
prepare the tablets. For this purpose, ethanol 
96 %v/v was employed as the granulation 
fluid while polyvinylpyrrolidone (PVP K10 was 
the binder. The other ingredients added to 
the formulation are sodium bicarbonate as 
gas-generating agent and magnesium 
stearate as lubricant.  To prepare the tablets, 
bupropion HCl was mixed with all the 
ingredients, except magnesium stearate, in a 
mortar. Next, alcohol solution of PVP (10 
%w/v) was added dropwise until a suitable 
mass for granulation was obtained, after 
which the wet mass was granulated through 
a 707 µm aperture sieve. The granules 
obtained were dried in an oven at 40 ˚C for 1 
h, passed through a 595 µm aperture sieve, 
blended with 0.5 % magnesium stearate and 
then compressed into tablets of 
approximately 400 mg each and hardness of 
6 - 8 kP.  
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Table 1: Composition (mg) of 150 mg bupropion HCl matrix tablets containing only HPMC as 
matrix former*  
* Each tablet contained 10 mg sodium bicarbonate and 2 mg magnesium stearate 
 










* Each tablet contained 10 mg sodium bicarbonate and 2 mg magnesium stearate 
 
Tablet friability was determined using 15 
tablets from each formulation in an Erweka 
TA Roche-type friabilitor at a speed of 25 rpm 
for 4 min. The hardness of 10 tablets was 
evaluated with an Erweka TBH 28 hardness 
tester, while the mean thickness of 10 tablets 
was measured using a caliper.   
           
In vitro buoyancy studies 
 
In vitro buoyancy of the tablets was 
determined by measuring floating lag time 
and duration of floating, according to the 
method described by Rosa et al [6]. In this 
method, one tablet was placed in a beaker 
containing 100 ml of 0.1M HCl. The time 
required for the tablet to rise to the surface 
was considered as the floating lag time. The 
total time that the tablet remained floating on 
the surface was also taken as duration of 
floating. These tests were carried out on 5 




In vitro dissolution studies 
 
Drug release studies were performed on only 
the formulations that show suitable floating 
behavior. The test carried out in 900 ml of 
0.1M HCl using a dissolution tester (Erweka, 
Germany) USP 23 type 2 apparatus (paddle 
method), at 50 rpm and 37 ˚C.  Samples (3 
ml each) were taken hourly for 10 h while 
keeping the dissolution medium volume 
constant by replenishing the dissolution 
medium with an equivalent amount of fresh 
medium to that withdrawn. The samples were 
filtered through a 0.45 µm membrane filter 
(Whatman no. 1) and diluted to a suitable 
concentration with 0.1M HCl. The 
absorbance of the samples was measured at 
252.5 nm using a Shimadzu UV-1201 
spectrophotometer. Cumulative drug release 
was calculated from the calibration curve of 
the drug standard. The results were 
expressed as mean ± standard deviation 




Ingredients A1 A2 A3 B1 B2 B3 C1 C2 C3 D1 D2 D3 E1 E2 F1 F2 
HPMC 
K4M 60 80 100    60 80 100    60 80   
HPMC 
K15M    60 80 100    60 80 100   60 80 
Avicel 158 138 118 158 138 118           
Lactose       158 138 118 158 138 118     
Tricalcium 
phosphate             158 138 158 138 
Ingredients G1 G2 G3 G4 H1 H2 H3 H4 
NaCMC 218 160 120 80 75 60 50 25 
HPMC 
K4M     25 40 50 50 
Avicel 0 58 98 138 118 118 118 118 
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Release kinetics 
 
In order to determine drug release kinetics, 
the release data were fitted to various kinetic 
models - zero order [7], first order [8], Higuchi 
[9] and Hixon-Crowell [10] as shown in Eqs 1 
– 4, respectively. 
      Qt = k0.t ………………………….……. (1) 
where Qt is the % drug release at time t and 
K0 is the release rate constant. 
 
       ln(100 ─ Q) = ln100 ─ k1.t ….…….. (2) 
where Q is % drug release and K1 is release 
rate constant. 
 
      Q = KH.t1/2 …………………………… (3) 
where Q is % drug release and KH is Higuchi 
release rate constant. 
 
      (100 ─ Q)1/3 = 1001/3 ─ KHC.t ……….. (4) 
where Q is % drug release and KHC is Hixon-
Crowell rate constant. 
Furthermore, a simple semi-empirical model 
(Korsemeyer-Peppas) was used to determine 
the drug release mechanism for the matrix 
tablets systems [11], as indicated in Eq 5. 
 
   
log log logt k p




                
where Qt is the amount of the released drug 
at time t, Q∞ is the overall amount of drug (the 
whole dose), kkp is the constant incorporating 
the structural and geometric characteristics of 
the controlled release device, and n is the 
release exponent indicative of drug release 
mechanism. For cylindrical geometries such 
as tablets n = 0.45 corresponds to Fickian 
diffusion, 0.45 < n < 0.89 to non-Fickian 
(anomalous) diffusion and n = 0.89 to case 2 
diffusion [12].  
 
In fitting data to the models, only points within 
the 10 - 60 % drug release range were used, 
except for the Higuchi model where the range 




All the results were expressed as mean 
values ± standard deviation (SD). Single-
factor analysis of variance (ANOVA) with a 
Tukey post-hoc test, at 5 % significance level, 
was used to compare buoyancy and drug 
release data. The analyses were performed 




Physical properties of bupropion tablets 
 
The hardness of all the tablet formulations 
ranged from 6 - 8 kP except for formulation 
G1 which contained 54.5 % NaCMC that 
exhibited a hardness of 5.3 kP. The friability 
of the tablets were within USP 23 limits [13], 
being < 1 %. The thickness of the tablets 
ranged from 3.10 - 3.64 mm.  
 
Buoyancy of tablets 
 
Buoyancy data are presented in Tables 3 and 
4.  
 
Table 3: Floating lag time and duration of floating of bupropion tablets containing HPMC as 
matrix former (mean ± SD, n = 5) 
 
Floating 
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Table 4: Floating lag time and duration of floating of bupropion tablets containing NaCMC or 
NaCMC/HPMC as matrix former (mean ± SD, n = 5). 
 
 
 It was observed that all the formulations 
containing HPMC (K4M or K15M) along with 
MCC had floating lag times < 30 s. A similar 
result was observed for formulations 
containing HPMC (K4M or K15M) plus 
lactose except for formulations C3 and D3 
which floated after 5.5 min and 50.8 s, 
respectively. All these formulations remained 
buoyancy for > 10 h. In contrast, none of the 
formulations containing tricalcium phosphate 
floated. 
 
The results from buoyancy studies on 
formulation batch series G showed that by 
increasing the amount of NaCMC and 
decreasing the amount of MCC, the time 
required for the tablets to float increased 
while the duration of floating decreased (p < 
0.05). Formulation G1 which did not contain 
MCC did not float at all while formulation G4 
which had the lowest concentration of 
NaCMC floated rapidly; however, due to the 
low concentration of polymer it disintegrated 
soon after floatation. In case of formulation 
series H, increasing HPMC K4M: NaCMC 
ratio has caused the tablets to float more 
quickly (p < 0.05). Formulation H1 with the 
highest amount of NaCMC floated for only 3 
h.  
 
Drug release profile 
 
Figures 1 and 2 show the drug release 
profiles of HPMC/MCC matrix tablets of 
bupropion prepared from formulation series 
A, B. C, D and H2 - H4.  
 
 
Figure 1: Effect of HPMC K4M content on 
bupropion HCl release from matrix tablets 
containing MCC in 0.1M HCl at 37 ± 0.5 ˚C. ■ = 
15% HPMC K15 (B1); ○ = 20% HPMC K4M (B2); 
▲ = 25% HPMC K4M (B3 ). 
 
 
Figure 2: Effect of HPMC K15M content on 
bupropion HCl release from matrix tablets 
containing MCC in 0.1M HCl at 37 ± 0.5 ˚C. ■ = 
15% HPMC K15 (B1); ○ = 20% HPMC K4M (B2);  
▲ = 25% HPMC K4M (B3). 
 
Raising the amount of HPMC reduced drug 
release rate (p < 0.05). Formulation series B 
Floating 



































±0.50 >10 >10 >10 
a Tablets did not float; b Tablets disintegrated soon after they floated 
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containing HPMC K15M showed slower drug 
release rate than formulation series A 
containing HPMC K4M.  
 
Figures 3 and 4 present the release profiles 
of drug from HPMC/lactose matrix tablets of 
bupropion. Like in formulation series A and B, 
drug release from formulation series C and D 
decreased as the content of HPMC 
increased. However, the effect of increasing 
HPMC content on drug release was more 
pronounced for tablets containing MCC than 
for those containing lactose.  
 
 
Figure 3: Effect of HPMC K4M content on 
bupropion HCl release from matrix tablets 
containing lactose in 0.1M HCl at 37 ± 0.5 ˚C. ■ = 
15% HPMC K4M (C1), ○ = 20% HPMC K4M (C2); 




Figure 4: Effect of HPMC K15M content on 
bupropion HCl release from matrix tablets 
containing lactose in 0.1M HCl at 37 ± 0.5 ˚C. ■ = 
15% HPMC K15M (D1); ○ = 20% HPMC K15M 
(D2); ▲ = 25% HPMC K15M (D3) 
 
The release profile of bupropion HCl from 
tablets containing varying ratios of HPMC 
K4M and NaCMC as the matrix is shown in 
Figure 5. The difference between drug 
release from matrices containing 2:3 and 3:1 
ratios of HPMC K4M:  NaCMC, i.e., 
formulations H4 and H2, was significant  (p < 
0.05). 
 
Figure 5: Effect of HPMC K4M:NaCMC ratio 
on bupropion HCl release from matrix tablets 
containing MCC in 0.1M HCl at 37.0 ± 0.5 ˚C. 




The values of kinetic rate constant (k), 
determination coefficient (r2) and release 
exponent (n) are presented in Table 5. The 
most appropriate model, based on the 
highest value of regression coefficient (r2), 
was Higuchi. Values of n obtained from 
Korsemeyer-Peppas model were between 





All the formulations had good physical 
properties. The low hardness of formulation 
G1 is due to the absence of MCC. The good 
floating ability of formulations series A, B, C 
and D is a result of the evolution of CO2 when 
sodium bicarbonate interacts with the 
dissolution medium which is acidic. 
Consequently entrapment of the gas (CO2) 
inside the hydrated polymeric matrix lowers 
the density of the tablet and thus causes the 
dosage form to float.  
 
Increasing the amount of polymer in the 
formulations   prepared   with   MCC  did   not 
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Table 5: Kinetic parameters for drug release from buproion HCl marix tablets. 
 
Kinetic 







































































































































































































































































































influence floating lag time of the tablets 
significantly. However, in formulations 
containing lactose, floating lag time increased 
when the content of HPMC was raised to 100 
mg. This may be attributed to the structural 
properties of MCC including swellable and 
porous structure and also low density of 
particles [14-16]. MCC gave such good 
floating properties to the formulations that 
increasing the polymer to sodium bicarbonate 
ratio in formulation series A and B did not 
increase floating lag time substantially. In 
contrast, increasing the polymer content to 
100 mg in formulation series C and D, where 
lactose was used in place of MCC, led to 
increase in floating lag time due to higher 
water absorption by the polymer making the 
matrix denser.  
 
Formulation series E and F did not float due 
to the insoluble nature of tricalcium 
phosphate which also imparted low porosity 
to the tablet matrix. Furthermore, the high 
density of tricalcium phosphate would also 
have enhanced the overall tablet density to a 
level above that of the simulated gastric fluid 
with the result that the tablets failed to float 
throughout the test period. 
 
Formulation series G prepared with NaCMC 
did not show good floating properties 
because NaCMC is a hydrophilic polymer 
with a high water absorption capacity and 
therefore, the tablets were weighed down in 
the medium by the absorbed fluid. Moreover, 
the gel layer formed by the polymer seems to 
be lower in strength than that formed by 
HPMC and, therefore, could not entrap the 
evolved gas efficiently. This is why increasing 
the proportion of NaCMC in its mixture with 
HPMC K4M (formulation series H), resulted 
in high floating lag time before the tablets 
floated.  
 
The reduction in drug release rate as polymer 
(HPMC) content or viscosity increased may 
be attributed to stronger gel formation. Highly 
viscous gels cause retardation of drug 
release [17,18]. Burst effect was observed in 
all the formulations due to rapid drug 
dissolution from the surface of the tablets. 
This effect was more pronounced at lower 
polymer concentrations. Furthermore, 
formulations containing MCC exhibited 
greater burst effect than those containing 
lactose, especially at a low polymer 
concentration (15 %) because of the 
disintegrating and swelling properties of 
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former. Subsequently, drug release from the 
tablets containing lactose accelerated over 
that from tablets formulated with MCC which 
is insoluble and therefore might have 
hindered drug release from the tablets. 
Increase in the proportion of HPMC K4M 
relative to that of NaCMC led to slower drug 
release because HPMC has capacity to form 
a more stable gel than NaCMC.  
 
When the release data were fitted to various 
kinetic models, the lowest regression 
coefficient (r2) values were yielded by the 
zero order model for a majority of the 
formulations. On the other hand, a majority of 
the formulations fitted best to the Higuchi 
model. Thus, drug release was principally 
controlled by diffusion. For formulations 
containing MCC, drug release might also 
have been dependent on drug concentration 
based on first order r2 values. Similarly, 
formulations containing lactose showed 
relatively high Hixon-Crowel r2 values, 
indicating a change in the surface and 
diameter of the tablets with progressive 
dissolution of the matrix as a function of time. 
Thus, when lactose is employed as a filler, 
changes in tablet surface and diameter is 
more likely to occur due to the soluble nature 
of lactose.  
 
Generally, the n values from the Korsemeyer-
Peppas relationship for all the formulations 
were > 0.45 which is indicative of drug 
release mechanism based on diffusion, 
swelling and erosion. Increasing the relative 
proportion of the polymer yielded higher n 
values, especially for formulation series of A 
and B. For both series, drug release at lower 
polymer contents was mainly governed by 
diffusion, while at higher polymer contents, 
the release mechanism shifted to anomalous 





Floating tablets of bupropion HCl were 
successfully developed in this study. HPMC 
is a matrix material for designing floating 
tablets and appropriate blending with NaCMC 
can yield floating tablets with suitable drug 
release and swelling characteristics. 
However, further studies, including in vivo 
investigations, are necessary to confirm the 
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